Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.
Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes posted first on https://www.youtube.com/dailyhealthpost/
No comments:
Post a Comment